anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Traumatic spinal cord injury (SCI) represents a complex neuropathological challenge that significantly impacts the well-being of affected individuals. The quest for efficacious antioxidant and anti-inflammatory therapies is both a compelling necessity and a formidable challenge. Here, in this work, the innovative synthesis of electron-rich Ru clusters on non-stoichiometric copper hydroxide that contain oxygen vacancy defects (Ru/def-Cu(OH)2), which can function as a biocatalytic reactive oxygen species (ROS) scavenger for efficiently suppressing the inflammatory cascade reactions and modulating the endogenous microenvironments in SCI, is introduced. The studies reveal that the unique oxygen vacancies promote electron redistribution and amplify electron accumulation at Ru clusters, thus enhancing the catalytic activity of Ru/def-Cu(OH)2 in multielectron reactions involving oxygen-containing intermediates. These advancements endow the Ru/def-Cu(OH)2 with the capacity to mitigate ROS-mediated neuronal death and to foster a reparative microenvironment by dampening inflammatory macrophage responses, meanwhile concurrently stimulating the activity of neural stem cells, anti-inflammatory macrophages, and oligodendrocytes. Consequently, this results in a robust reparative effect on traumatic SCI. It is posited that the synthesized Ru/def-Cu(OH)2 exhibits unprecedented biocatalytic properties, offering a promising strategy to develop ROS-scavenging and anti-inflammatory materials for the management of traumatic SCI and a spectrum of other diseases associated with oxidative stress.
Subjects were willing to provide 2 samples of saliva, dental plaque and gingival fluid (gum fluid), on the first day (before consuming lozenges) and on the 14th day after the subject consumed lozenges containing L. reuteri probiotic. Probiotics are taken once a day for two weeks after breakfast and brushing their teeth.
The incidence rate of hypertriglyceridemia pancreatitis (HTGP) has experienced a notable increase in recent years, with eclipsing alcohol as the second leading cause of acute pancreatitis (AP). HTGP is often associated with more severe local and systemic complications. Recognized as a metabolic disorder hypertriglyceridemia (HTG), it holds significant relevance in the pathogenesis of HTGP, yet its mechanisms are not fully understood. Both primary (genetic) and secondary (acquired) factors contribute to elevated triglyceride (TG) levels, which concurrently influence the progression of HTGP. This article presents a comprehensive review of the evolving research on HTGP pathogenesis, encompassing lipid synthesis and metabolism, calcium signal transduction, inflammatory mediators, endoplasmic reticulum stress, autophagy, mitochondrial injury by fatty acids, oxidative stress response, genetic factors, and gene mutations. By unraveling the intricate mechanisms underlying HTGP, this article aims to enhance physicians' understanding of the disease and facilitate the development of potential targeted pharmacological interventions for patients.
At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
Introduction: In this study, we will use anodal direct current (DC) polarization at 2 mA to treat patients with frontotemporal dementia (FTD). Currently, there is no effective treatment for these patients. Previously, in healthy volunteers, we observed that DC polarization of the left prefrontal area for 20 min safely increases verbal fluency, cognitive processing speed (working memory and attention) and motor reaction speed. Both of these functions are severely impaired in FTD. Objective: We wish to see whether anodal DC polarization of the left prefrontal cortex in FTD patients leads to improvement in verbal fluency and working memory. Design: In this pilot study, we propose to treat six FTD patients for 40 min with anodal and sham DC polarization in a single-blind, crossover design. Outcome Measures: The main outcome measures will be verbal fluency and working memory. If anodal DC polarization produces clinically relevant improvements in these patients this will provide the impetus for a larger trial.
Patients receive DA-EPOCH regimen comprising doxorubicin hydrochloride IV, vincristine sulfate IV, and etoposide IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 1-2 hours on day 5; and prednisone PO BID on days 1-5. Patients also receive ofatumumab IV over 2 hours on days 1, 2, and 11 of cycle 1; on days 1 and 8 of cycles 2 and 4; and on days 1 and 11 of cycle 3 for a total of 9 injections. Patients may receive rituximab instead of ofatumumab if their insurance provider does not cover the cost of ofatumumab. Patients receive rituximab IV over 2 hours on days 1 and 11 of cycles 1 and 3 and on days 2 and 8 of cycles 2 and 4. Treatment repeats every 21-28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To judge the presence of an intestine disease or a kidney disease by measuring the concn. of glycentine in a blood plasma specimen of a subject to compare the same with that of a healthy person. SOLUTION: In the measurement of the concn. of glycentine in a blood plasma specimen, an anti-human glycentine antibody is solidified and the blood plasma specimen is reacted with the solid phase antibody and, next, a labelled anti-human glycentine antibody different from the anti-human glycentine antibody solidified in the beginning in the region recognition part of human glycentine amino acid sequence is reacted and an amt. of this reacted labelled anti-human glycentine antibody is measured. Herein, when the value of the concn. of glycentine in the blood plasma sample of a subject is twice-below fiber times as compared with that of a healthy person, a clone disease of an active period is judged. When the value of the subject is five times of more as compared with the value of the healthy person, a kidney disease is judged.
Long non-coding RNAs (lncRNAs) are a diverse class of RNA molecules that do not code for proteins but play critical roles in gene regulation. One such role involves the modulation of cell cycle progression and proliferation through interactions with cyclin-dependent kinases (CDKs), key regulators of cell division. Dysregulation of CDK activity is a hallmark of cancer, contributing to uncontrolled cell growth and tumor formation. These lncRNA-CDK interactions are part of a complex network of molecular mechanisms underlying cancer pathogenesis, involving various signaling pathways and regulatory circuits. Understanding the interplay between lncRNAs, CDKs, and cancer biology holds promise for developing novel therapeutic strategies targeting these molecular targets for more effective cancer treatment. Furthermore, targeting CDKs, key cell cycle progression and proliferation regulators, offers another avenue for disrupting cancer pathways and overcoming drug resistance. This can open new possibilities for individualized treatment plans and focused therapeutic interventions.
Kidney stones are primarily formed due to the supersaturation of ions in urine, leading to the formation of crystals. An assessment of the risk of kidney stones is based on a patient's medical history, biochemical urine tests, and various laboratory examinations. Combining these with imaging studies such as CT scans, ultrasound, and X-rays helps in diagnosing the type of kidney stones, though imaging results for smaller stones may be less accurate. Stone formation is common with a high recurrence rate, and there is a strong correlation between urine crystals and stone composition. Therefore, the analysis of urine crystals is meaningful for the diagnosis, evaluation of treatment strategies, and prevention of stone recurrence in kidney stone disease.

Microscopic analysis of urine crystals allows the observation of smaller crystals. However, manual urine microscopy is slow and time-consuming. To address this, we aim to develop artificial intelligence software to assist in the interpretation of urine crystals, providing a faster analysis. We will retrospectively analyze urine crystal images stored from previous research (Chang Gung Memorial Hospital Internal Project Research No. 107123-E) to identify crystal types. Subsequent image preprocessing and category labeling will be done to train and infer machine software. The results will be compared with manual interpretation to establish the accuracy of the software.
PCT No. PCT/US91/02052 Sec. 371 Date Sep. 11, 1992 Sec. 102(e) Date Sep. 11, 1992 PCT Filed Mar. 20, 1991This invention describes a process for producing single cell edible oils containing eicosapentaenoic acid (EPA) from heterotrophic diatoms. The diatoms are cultivated in a fermentor in a nutrient solution containing nitrogen and silicate. Depletion of the nitrogen followed by depletion of the silicate induces the diatoms to synthesize large quantities of edible oil containing EPA which subsequently is recovered. The edible oil, and uses for it, also form parts of this invention as do mutant diatoms capable of producing large quantities of EPA.
Princess lite is a cream used to treat and manage breast health. It has been effective in dissolving cyst and tumors, benign and malignant, in the breast and other parts of the body. It begins working on first use. It is most effective when used together with heat therapy at least 1½-2 hours daily on inflicted site. It dissolved within a two month period; however, it began minimizing the tumors immediately. 
     The garlic helps fight off virus and bacterial infections. The coconut oil increases your energy, boost your metabolism, supports immune health, promotes antiviral, antifungal, and antibacterial activity. Castor oil is a natural laxative, it benefits lymphatic system increasing the production of lymphocytes and helping to remove toxins from the body. Pau D'Arco is to fight infection and is used to treat various forms of cancer.
The present invention discloses a scar inhibitor and a preparing method thereof. The scar inhibitor comprises methyl vinyl polysiloxane, methyl silicone oil, silicone gel and solvent ether or xylene. The components are mixed and prepared according to a certain proportion and technological procedures, so that a macromolecular aerosol for external application can be prepared. The scar inhibitor can be directly sprayed to a healed wound surface or a scar surface so as to form a film after the scar inhibitor is naturally dried. Thus, use is convenient. The scar inhibitor has an obvious inhibition function for scar tissue hyperplasia by clinical probation, can prevent the formation of scars when applied to healed wound surfaces in an early stage, and can obviously inhibit the continuous hyperplasia of scars when applied to hyperplastic scars in an intermediate stage.
PCT No. PCT/EP96/03605 Sec. 371 Date Jul. 31, 1997 Sec. 102(e) Date Jul. 31, 1997 PCT Filed Aug. 14, 1996 PCT Pub. No. WO97/14719 PCT Pub. Date Apr. 24, 1997A bispecific or bivalent double head antibody fragment, which is composed of a binding complex containing two polypeptide chains, whereby one polypeptide chain has two times a variable domain of a heavy chain (VH) in series and the other polypeptide chain has two times a variable domain of a light chain (VL) in series, and the binding complex contains two pairs of variable domains (VH-A//VL-A and VH-B//VL-B), wherein said double head antibody fragments have binfunctional antigen binding activity. A process for producing such an antibody fragment is disclosed. An immunoassay is also provided for, wherein the improvement is the inclusion of a bispecific or bivalent double head antibody fragment, which is composed of a binding complex containing two polypeptide chains, whereby one polypeptide chain has two times a variable domain of a heavy chain (VH) in series and the other polypeptide chain has two times a variable domain of a light chain (VL) in series, as a binding means.
Disorders of the gut-brain interaction (DGBIs) are presently classified into mutually exclusive anatomical area-related symptom-based categories according to the Rome IV criteria. The pathophysiology of visceral nociception, which contributes to the wide range of symptoms of DGBIs, involves complex psychobiological processes arising from the bidirectional interactions of multiple systems at the gut and brain levels, which affect symptom expression and illness behaviors. The attitude toward an illness and expression of pain and bowel habit vary across cultures with variable interpretation based on sociocultural beliefs, which may not tally with the medical definitions. Thus, psychological factors impact DGBI definitions, their severity and health care utilization. Due to the poor localization and multisegment referral of visceral pain, the anatomical site of pain may not correspond to the affected segment, and there may be a variable degree of overlap among symptoms. The somewhat restrictively defined Rome IV criteria assume one-to-one correlation of symptoms with underlying pathophysiology and ignore overlapping DGBIs, nonstandardized symptom categories, and change or shift in category over time. The microorganic nature of DGBIs resulting from systemic, metabolic or motility disorders, gut dysbiosis and inflammation are not addressed in the Rome IV criteria. Although there is a multidimensional clinical profile that does address these factors, it is not followed rigorously in practice. Threshold changes for diagnostic criteria or addition/deletion of symptoms leads to wide variation among different DGBI criteria resulting in uncertain comparability of results. Although the Rome IV criteria are excellent for research studies and therapeutic trials in homogenous populations, further improvement is needed for their wider applicability in clinical practice.
Understanding the mechanism underlying the evolution of knuckle-walking in African great apes but not in humans may provide important implications about the origin and evolution of human bipedal locomotion. In this study, aiming to reveal possible structural adaptations of the chimpanzee's forearm and hand musculature related to knuckle-walking, we measure the passive elastic moment of the chimpanzee's and orangutan's wrist as it was rotated into extension, immobilizing the metacarpophalangeal joint at three different positions: extended (as in knuckle-walking), flexed (as in fist-walking), and an intermediate position. Our findings demonstrate that when the metacarpophalangeal joints are extended, the rigidity of the wrist joint in the extended direction increases. This increased rigidity is attributed to the passive elongation and force generation of digital flexor muscles, which are relatively short in chimpanzees. Consequently, this enhanced wrist-joint rigidity contributes to the stability and energetically efficient transmission of propulsive force to the ground during the stance phase. Overall, our study supports the hypothesis that knuckle-walking is an adaptation to terrestrial locomotion for an ancestor characterized by the restricted capacity for wrist extension owing to the relatively shorter tendons of digital flexor muscles.
Body temperature must be monitored in patients receiving Hospital-at-Home (HaH) care for COVID-19 and other infectious diseases. Continuous temperature telemonitoring (CTT) detects fever and patient deterioration early, facilitating decision-making. We performed a validation clinical study assessing the safety, comfort, and impact on healthcare practice of Viture®, a CTT system, compared with a standard digital axillary thermometer in 208 patients with COVID-19 and other infectious diseases treated in HaH at the Navarra University Hospital (HUN). Overall, 3258 pairs of measurements showed a clinical bias of -0.02 °C with limits of agreement of -0.96/+0.92 °C, a 95% acceptance rate, and a mean absolute deviation of 0.36 (SD 0.30) °C. Viture® detected 3 times more febrile episodes and revealed fever in 50% more patients compared with spot measurements. Febrile episodes were detected 7.23 h (mean) earlier and modified the diagnostic and/or therapeutic approach in 43.2% of patients. Viture® was validated for use in a clinical setting and was more effective in detecting febrile episodes than conventional methods.
Procedure for preparing an antitumoral agent containing the lactobacillus casei yit 9018 stem. Cells are inoculated, live or dead by heat, of lactobacillus casei yit 9018 in a certain composition of cultivation brown and are cultivated in certain temperature conditions and cultivation time. Cells are filtered from the cultivated liquid through centrifugation and washed with distilled water. The suspension so obtained is distributed in ampollas and it is lyophilized. The antitumoral agent can be obtained as liquid, dust or granules; existing varieties in the processes of obtaining. (Machine-translation by Google Translate, not legally binding)
To provide a skin wrinkle improvement agent, a skin wrinkle improvement method in which shape change of a skin surface is an index, and a screening method therefor.SOLUTION: There is provided (1) a screening method of a skin wrinkle improvement agent and/or improvement method in which cell shape change on a skin horny layer is an index. There is also provided (2) a screening method in which the cell shape change is comparison between a skin wrinkle part horny layer cell area and a skin non-wrinkle part horny layer cell area, before and after application of a test substance or a test method. There is also provided (3) a skin wrinkle improvement agent and/or improvement method selected by the screening method described in (1) or (2). There is also provided (4) a screening method of the skin wrinkle improvement agent in which the cell shape change of an epidermal keratinocyte by artificial expansion/shrinkage load to the epidermal keratinocyte is an index. There is also provided (5) a screening method of the skin wrinkle improvement agent including a step for evaluating a cell shape change control effect of the epidermal keratinocyte of the test substance. There is also provided (6) a skin wrinkle improvement agent selected by the screening method described in (4) or (5).SELECTED DRAWING: Figure 1
Disclosed are methods for separating, recovering, and purifying cannabidiolic acid (CBDA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids in C5-C7 hydrocarbon solvents, adding thereto a selected amine to thereby precipitate a CBDA-amine salt therefrom, dissolving the recovered CBDA-amine salt in a selected solvent and then adding thereto a selected antisolvent to thereby recrystallizing a purified CBDA-amine salt therefrom. The recrystallized CBDA-amine salt may be decarboxylated to form a mixture of cannabidiol (CBD) and amine. The CBD amine mixture may be acidified to separate the amine from CBD. The recovered CBD may be concentrated to produce a highly purified CBD. Also disclosed are CBDA-amine salts produced with certain amines selected from groups of secondary amines, tertiary amines, diamines, amino alcohols, amino ethers, and highly basic amines.
Eligible pregnant women would be randomized to intervention or the non-intervention arm after consenting to participate. Participants in the intervention arm will receive free subscription of m-Health program for six months of coaching. The program will provide individualized coaching on diet, supplement use and physical activity. Participants would undergo dietary screening at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow-up to monitor the improvement (if any) in diet, supplement use and physical activity. Women will receive advice in the form of recommendations after completing the questionnaire. Also, push messages containing tips and recommendations for diet, supplement use and physical activity would be delivered a maximum of three times a week. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line.
Mount Vernon Cancer Centre at East and North Hertfordshire NHS Trust offers patients with certain cancers a treatment called adaptive radiotherapy. The aim of adaptive radiotherapy is to respond to physical changes that occur during treatment to ensure the radiation continues to be directed at the cancer and to minimise the amount of healthy tissue treated. For example, if tumour shrinkage or weight loss occurs during head and neck radiotherapy the patient may have a repeat CT scan and a new radiotherapy treatment plan after a few weeks of treatment. For patients with cancer of the bladder or cervix changes in bladder and uterus size and position can be predicted allowing the prospective creation of three radiotherapy treatment plans, each day the best fitting plan, i.e. the one that closely covers the tumour whilst giving minimal dose to normal tissues, is selected and used for treatment, this is known as plan-of-the-day adaptive radiotherapy.

Small changes in shape and position of the prostate occur but are generally the result of rectal changes which cannot be predicted, consequently adaptive radiotherapy based on physical change is not possible for prostate cancer treatments. However, recent literature suggests that magnetic resonance imaging (MRI) can detect changes within the prostate in response to radiotherapy, some studies have seen changes as early as the second week of radiotherapy treatment. A feasibility study to investigate if these changes can support radiotherapy treatment plan adaption for prostate cancer treatments is proposed, whether the plan can be adapted to give a higher treatment dose to any areas of the prostate that show poor response to radiotherapy without increasing bowel and bladder dose is of particular interest. The treatment for patients who participate in the study would not be changed but the results may help to personalise and improve the treatment of future patients.
The invention relates to a cell inactivated vaccine, an egg yolk antibody injection and a preparation method of the cell inactivated vaccine. The cell inactivated vaccine comprises a porcine circovirus antigenic epitope and a goose circovirus antigenic epitope. The preparation method of the cell inactivated vaccine comprises the following steps: firstly screening high-pathogenicity strains from the porcine circovirus, then selecting a plurality of virus epitopes having antibody immunocompetence from the strains, inserting the point of the porcine circovirus antigenic epitope into a goose circovirus genome by technologies such as purification and clone, and then carrying out viral multiplication in a large scale to obtain the cell inactivated vaccine. The invention also discloses the egg yolk antibody injection taking the cell inactivated vaccine as an antibody at the same time, the injection can be used for treating porcine circovirus diseases, takes effect quickly and has remarkable effects, meanwhile, a small dose can also be used for preventing the occurrence of the porcine circovirus diseases, so that the incidence rate is reduced and the economic benefit is improved. Meanwhile, the egg yolk antibody can also be used for treating the goose circovirus diseases. The preparation has lower stimulation on a human body, the working efficiency is further improved, and the feeding cost is lowered.